Aliakbar Fazaeli

Aliakbar Fazaeli

Auto-generated profile, based on publicly available information

Aliakbar Fazaeli

Department of Biochemistry, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMohammad Hashemi
Mohammad Hashemi
AFAliakbar Fazaeli
Aliakbar Fazaeli
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
EEEbrahim Eskandari-Nasab
Ebrahim Eskandari-Nasab
FAFarshid Arbabi
Farshid Arbabi
Marek J. ŁosMarek J. Łos
Marek J. Łos
Fas/Fas ligand (FasL) system is one of the key apoptotic signaling entities in the extrinsic apoptotic pathway. De-regulation of this pathway, i.e. by mutations may prevent the immune system from the removal of newly-formed tumor cells, and thus lead to tumor formation. The present study investigated the association between −1377 G/A (rs2234767) and −670 A/G (rs1800682) polymorphisms in Fas as well as single nucleotide polymorphisms INV2nt −124 A/G (rs5030772) and −844 C/T (rs763110) in FasL in a sample of Iranian patients with breast cancer. This case-control study was done on 134 breast cancer patients and 152 normal women. Genomic DNA was extracted from whole blood samples. The polymorphisms were determined by using tetra-ARMS-PCR method. There was no significant difference in the genotype distribution of FAS rs2234767 polymorphism between cases and controls. FAS rs1800682, FASL rs5030772, and FASL rs763110 genotypes showed significant associations with an increasing risk of breast cancer (odds ratio OR = 3.18, P = 0.019; OR = 5.08, P = 0.012; OR = 2.40, P = 0.024, respectively). In conclusion, FAS rs2234767 was not associated with breast cancer risk. Though, FAS rs1800682, FASL rs5030772, and FASL rs763110 polymorphisms were associated with the risk of breast cancer in the examined population.

29 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RFReza Fadaei
Reza Fadaei
NMNariman Moradi
Nariman Moradi
MBMehdi Baratchian
Mehdi Baratchian
HAHassan Aghajani
Hassan Aghajani
MMMojtaba Malek
Mojtaba Malek
SFSoudabeh Fallah
Soudabeh Fallah
C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 are two newly discovered adipokines regulating glucose and lipid metabolism. But their role in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) is still in infancy. The aim of this study was to investigate the associations of gene expression and serum levels of CTRP3 and CTRP13 with CAD, metabolic and inflammatory markers in patients with and without T2DM. Serum levels of CTRP3, CTRP13, adiponectin and inflammatory cytokines and their gene expression in peripheral blood mononuclear cells (PBMCs) were determined in 172 subjects categorized as group I (without T2DM and CAD), group II (with CAD but no T2DM), group III (with T2DM but no CAD) and group IV (with T2DM and CAD). Serum levels and gene expression of CTRP3, CTRP13 and adiponectin in the group I were higher compared to other groups. Inflammatory cytokines in the control group were lower than other groups too. CTRP3 serum levels have an independent association with BMI, smoking and CTRP3 gene expression; also CTRP13 serum levels has an independent association with BMI, HDL-C, insulin, HOMA-IR, HbA1c and TNF-α. Decreased serum levels of CTRP3 and CTRP13 were also associated with CAD. It appears that the decreased levels of CTRP3 and especially CTRP13 were associated with increased risk of T2DM and CAD. These findings suggest an emerging role of these adipokines in the pathogenesis of CAD, but further studies are necessary to establish this concept.

1 May 2012 in DNA and Cell Biology
Verified
Journal Article
Closed access
MHMohammad Hashemi
Mohammad Hashemi
EEEbrahim Eskandari-Nasab
Ebrahim Eskandari-Nasab
AFAliakbar Fazaeli
Aliakbar Fazaeli
ABAli Bahari
Ali Bahari
NHNoor-Allah Hashemzehi
Noor-Allah Hashemzehi
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
Oxidative damage is thought to play a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Glutathione-S-transferases (GSTs) are involved in cell protection against oxidative stress. We examined whether GSTM1, GSTT1, and GSTP1 polymorphisms are associated with NAFLD in a sample of the Iranian population. The current case–control study included 83 patients with NAFLD and 93 healthy subjects. The GSTM1 and GSTT1 polymorphisms were analyzed by multiplex polymerase chain reaction (PCR). The GSTP1 polymorphism was detected by tetra amplification refractory mutation system-PCR assay. The GSTM1-null genotype was significantly associated with the development of NAFLD (odds ratios [OR]=2.171, 95% confidence intervals [CI]=1.188–3.970, p=0.015). The GSTP1 Val allele was shown to be a risk factor for NAFLD (OR=1.739, 95% CI=1.089–2.777, p=0.024). The GSTT1 polymorphism was not significantly different between control and patient groups (p=0.221). This study showed that GSTM1 and GSTP1, but not GSTT1, genetic polymorphisms are associated with NAFLD in a sample of the Iranian population, and may be used to determine the risk of development of NAFLD.

11 December 2012 in Biomarkers in Medicine
Verified
Journal Article
Closed access
MHMohammad Hashemi
Mohammad Hashemi
EEEbrahim Eskandari-Nasab
Ebrahim Eskandari-Nasab
AFAliakbar Fazaeli
Aliakbar Fazaeli
MTMohsen Taheri
Mohsen Taheri
HRHamzeh Rezaei
Hamzeh Rezaei
GBGholamreza Bahari
Gholamreza Bahari
Genetic and environmental factors are risk factors for breast cancer. Our aim was to investigate the associations between genetic polymorphism of GST genes (GSTM1, GSTT1 and GSTP1) and susceptibility to breast cancer in an Iranian population. This case-control study was carried out on 134 patients with breast cancer and 152 healthy, cancer-free women. GSTP1 polymorphism was determined using tetra-primer amplification refractory mutation system PCR assay and GSTM1 and GSTT1 were genotyped by a multiplex PCR. We found that the GSTM1 null genotype is a risk factor for predisposition to breast cancer (odds ratio [OR] = 2.01; 95% CI = 1.78-3.45; p = 0.010). No significant difference was found between the groups regarding GSTT1 null genotype (p > 0.05). The GSTP1 Ile/Val and Val/Val genotypes were associated with breast cancer risk (OR = 3.29; 95% CI = 1.84-5.91; p < 0.0001 and OR = 20.68; 95% CI = 5.66-75.60; p < 0.0001, respectively). In summary, GSTM1 and GSTP1, but not GSTT1 genetic polymorphisms are associated with increased risk of breast cancer in our population.

1 August 2012 in Gene
Verified
Journal Article
Closed access
MHMohammad Hashemi
Mohammad Hashemi
EEEbrahim Eskandari-Nasab
Ebrahim Eskandari-Nasab
AFAliakbar Fazaeli
Aliakbar Fazaeli
HRHamzeh Rezaei
Hamzeh Rezaei
MMMohammad Ali Mashhadi
Mohammad Ali Mashhadi
MTMohsen Taheri
Mohsen Taheri

7 October 2012 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
EEEbrahim Eskandari-Nasab
Ebrahim Eskandari-Nasab
MHMohammad Hashemi
Mohammad Hashemi
HRHamzeh Rezaei
Hamzeh Rezaei
AFAliakbar Fazaeli
Aliakbar Fazaeli
MMMohammad Ali Mashhadi
Mohammad Ali Mashhadi
MTMohsen Taheri
Mohsen Taheri